As we investigated the presence of other inhibitory markers, such as TIM-3 and LAG-3, there are no significant differences in the expression of TIM-3 and LAG-3 in CD4 T cells derived from lymph nodes of tumor-bearing mice (Supplementary fig. 7j), as well as in tumor-infiltrating CD4 T cells (Supplementary Fig. 7k) of tumor-bearing mice after treatment with methionine or AICAR supplementation or methionine and AICAR co-treatment. This evidence concerns the gene HAVCR2 and neoplasm.